Author Archives: Pure Protein LLC

Pure Protein L.L.C. Appoints Dr. Rico Buchli as Chief Scientist

OKLAHOMA CITY, Okla. /ScoopCloud/ -- Pure Protein L.L.C. proudly announces the appointment of Dr. Rico Buchli as Chief Scientist. In his new role, Dr. Buchli will lead scientific initiatives and oversee the expansion of the company's immunological products and services portfolio. This strategic move underscores Pure Protein's commitment to providing innovative, high-quality reagents to the global research and diagnostics community.

Dr. Buchli has a distinguished career spanning over two decades, including 23 years as Pure Protein's Director of Research and 3 years as Vice President of Products and Services. He is renowned for his pioneering work in soluble HLA technology, significantly impacting immunotherapy research, particularly in transplant diagnostics and antigen-targeting platforms. His contributions have advanced research in oncology, infectious diseases, and autoimmune diseases, positioning Pure Protein as a leader in HLA reagents and assay platforms.

As Chief Scientist, Dr. Buchli will focus on expanding and refining Pure Protein's product offerings, with an emphasis on delivering superior HLA solutions for research in immunotherapy, transplant diagnostics, and cancer immunology. This will include the development of recombinant monomers, tetramers, and assay platforms essential for T-cell analysis, vaccine development, and understanding autoimmune disorders. His leadership will drive the company's innovation, ensuring the development of customized solutions for its clients while maintaining the highest standards of scientific rigor.

"We are excited to announce the promotion of Dr. Buchli to Chief Scientist," said Tommy Harlan, CEO. "Under his leadership, Pure Protein is poised to continue its legacy of scientific excellence, advancing immunology, oncology, and personalized medicine while expanding its impact on the global research community."

As VP of Products and Services, Dr. Buchli will spearhead efforts to broaden Pure Protein's global reach by fostering collaborations with leading pharmaceutical companies, research institutions, and clinical laboratories, ensuring the accessibility of Pure Protein's cutting-edge tools for medical research. A key priority will be expanding the company's HLA product portfolio to meet growing demand in therapeutic areas by aligning product development with the needs of researchers and clinicians to provide high-quality tools and reagents that drive groundbreaking discoveries.

About Pure Protein, L.L.C.

Pure Protein is a platform technology company funded and managed by Emergent Technologies Inc. For more information about Pure Protein LLC, please visit: http://www.hlaprotein.com/

About Emergent Technologies, Inc.

Emergent Technologies is an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: http://www.etibio.com/

Pure Protein L.L.C. proudly announces the appointment of Dr. Rico Buchli as Chief Scientist. In his new role, Dr. Buchli will lead scientific initiatives and oversee the expansion of the company's immunological products and services portfolio. This strategic move underscores Pure Protein's commitment to providing innovative, high-quality reagents to the global research and diagnostics community.

Related link: https://www.hlaprotein.com/

Pure Protein, LLC and Pure Transplant Solutions, LLC Promote Blake Harlan to President and Dr. Rico Buchli to Vice President of Products and Services

AUSTIN, Texas /ScoopCloud/ -- Pure Protein, LLC (Pure Protein) and subsidiary company Pure Transplant Solutions, LLC (PTS), announced today that Blake Harlan has been promoted to President and Rico Buchli, PhD to Vice President of Products and Services.

In his new role, Mr. Harlan will be responsible for leading Pure Protein's new product line commercialization while ensuring sustainable profitability and growth. He will also oversee the implementation and launch of Pure Transplant Solutions clinical diagnostics and transplant monitoring programs.

Going forward, Dr. Buchli will now be responsible for overseeing the products and services offered through HLAProtein.com in addition to expanding the portfolio of the companies' offerings. Furthermore, he will have the scientific oversight for the completion and launch of Pure Transplant Solutions' diagnostic products and monitoring programs.

"It's truly an exciting time for the Companies," said Mr. Harlan. "In the past twelve months we've built and launched our new website, established a robust pipeline of collaborations and developed new diagnostics for post-transplant monitoring. We've made the transformation from being a company solely developing technologies, to a company putting our products and tools in the hands of clinicians and researchers. We'll be launching a slate of new products and applications over the next several months and are all very excited for 2021."

"We wanted to build something more than just a website where you could place orders, we wanted to create a centralized resource for HLA research and education," said Dr. Buchli. "We've worked hard to incorporate the feedback from our collaborators and customers and are excited about the new products and services we'll be adding in the near future. In transplantation, we have ambitious goals and are optimistic about delivering solutions that improve patient outcomes."

Dr. Buchli earned his Ph.D. in Biochemistry from the University of Basel in 1996. He served as Postdoctoral Researcher at UC Davis under Drs. Sergei Grando and Dick Robbins and joined Pure Protein, LLC in March of 2001 as the Director of Research. Dr. Buchli has over 25 years of experience in molecular biology, biochemistry and immunology. As Director of Research, Dr. Buchli has developed multiple assay systems and has led the development of PTS's diagnostics portfolio.

Blake Harlan joined Emergent Technologies, Inc. (ETI) in January 2011, where his work and increasing responsibilities have focused on the commercialization of technologies spanning antimicrobials, plasma deposition, drug delivery, and immune oncology. He officially joined Pure Protein and PTS in 2016 and has been responsible for streamlining PTS's diagnostic development and commercialization strategies. He currently serves as Executive Vice President of Finance and Operations at ETI where he oversees the alignment and execution of all financial and operational objectives for ETI, its Funds and Portfolio Companies. Mr. Harlan holds a bachelor's degree in Economics from the University of Colorado at Boulder, and an MBA from the University of Texas at Austin.

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies, products and services related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma.

Through its new ecommerce website, http://www.hlaprotein.com/, Pure Protein now offers the world's only and largest selection of soluble HLA (sHLA) proteins to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 2003 in order to leverage the HLA technology platform of its parent, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Today, PTS has developed a portfolio of diagnostic solutions to improve clinical outcomes related to antibody mediated rejection (AMR) and is working with collaborators to bring personalized transplant monitoring solutions to clinicians and their patients. Visit: http://www.puretransplant.com/

*PHOTO link for media: https://www.Send2Press.com/300dpi/21-0204s2p-harlan-and-buchli-300dpi.jpg

*Caption: Pure Protein, LLC and Pure Transplant Solutions, LLC Promote Blake Harlan to President and Dr. Rico Buchli to Vice President of Products and Services.

Pure Protein, LLC (Pure Protein) and subsidiary company Pure Transplant Solutions, LLC (PTS), announced today that Blake Harlan has been promoted to President and Rico Buchli, PhD to Vice President of Products and Services.

Related link: https://www.hlaprotein.com/

Pure Protein, LLC Announces New Website Now Offering Its HLA Reagents and Technical Services to Researchers

OKLAHOMA CITY, Okla. /ScoopCloud/ -- Pure Protein, LLC (Pure Protein) an HLA company that has developed comprehensive analytical capabilities in the field of human leukocyte antigen (HLA) immunology and an approach to produce soluble forms of the HLA molecule (sHLA), is proud to announce the launch of its new website https://www.hlaprotein.com/.

This new ecommerce website offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

Rico Buchli, Ph.D., Pure Protein's Director of Research commented, "For over 20 years, Pure Protein has provided technology and expertise to advance novel therapies and diagnostic tools for applications in transplantation, oncology, autoimmunity, and infectious disease."

He added, "We are excited to now have a website where researchers can easily explore and purchase our inventory of over 250 Class I and Class II proteins in both unmodified and biotinylated forms and Pure Protein's peptide validation, screening and mapping services."

The website is a comprehensive source for HLA proteins, services and scientific resources that will be updated on a regular basis with new products, technical updates and company milestones. For more information visit https://www.hlaprotein.com/.

About Pure Protein, LLC

Pure Protein, L.L.C. is a biotechnology company focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma in 1999. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation. Visit: http://www.pureproteinllc.com/.

Pure Protein is funded and managed by Emergent Technologies, Inc. an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: http://www.emergenttechnologies.com/.

*LOGO link for media: https://www.Send2Press.com/300dpi/20-1125s2p-hla-protein-300dpi.jpg

Pure Protein, LLC (Pure Protein) an HLA company that has developed comprehensive analytical capabilities in the field of human leukocyte antigen (HLA) immunology and an approach to produce soluble forms of the HLA molecule (sHLA), is proud to announce the launch of its new website.

Related link: https://www.hlaprotein.com/

Pure Protein, LLC to Exhibit and Preview New Website at the American Society for Histocompatibility and Immunogenetics (ASHI) 46th Annual Meeting

OKLAHOMA CITY, Okla. /ScoopCloud/ -- Pure Protein, LLC (Pure Protein) an HLA company that has developed comprehensive analytical capabilities in the field of human leukocyte antigen (HLA) immunology and an approach to produce soluble forms of the HLA molecule (sHLA), announced today that it will be an exhibitor at the ASHI VIRTUAL ANNUAL MEETING, October 19 - 21, 2020, where the Company will be previewing its soon to launch website https://www.hlaprotein.com/.

This new website will offer academic and commercial researchers access to individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

Rico Buchli, Ph.D., Pure Protein's Director of Research commented, "For over 20 years, Pure Protein has provided technology and expertise to advance novel therapies and diagnostic tools for applications in transplantation, oncology, autoimmunity, and infectious disease."

He added, "We are excited to exhibit at ASHI 2020 and share the news about hlaprotein.com where we will soon be offering researchers 126 Class I and 154 Class II proteins in both unmodified and biotinylated forms, as well as access to Pure Protein's peptide validation, screening and mapping services."

About Pure Protein, LLC

Pure Protein, L.L.C. is a biotechnology company focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma in 1999. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation. Visit: https://www.hlaprotein.com/.

Pure Protein is funded and managed by Emergent Technologies, Inc. an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: https://emergenttechnologies.com/.

Link to event information: https://www.ashi-hla.org/page/Meetings_Annual

Pure Protein, LLC (Pure Protein) an HLA company that has developed comprehensive analytical capabilities in the field of human leukocyte antigen (HLA) immunology and an approach to produce soluble forms of the HLA molecule (sHLA), announced today that it will be an exhibitor at the ASHI VIRTUAL ANNUAL MEETING, October 19 - 21, 2020.

Related link: https://www.hlaprotein.com/